What's New

Transfer of Marketing Authorization for humanized anti EGFR Monoclonal Antibody PORTRAZZA, in JAPAN

2019/06/18

 Tokyo, Japan, June 18th , 2019 - Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Masanobu Suzuki; hereinafter referred to as “Nippon Kayaku”) and Eli Lilly Japan K.K. (Head Office: Hyogo; Representative Director and President: Patrik Jonsson ; hereinafter referred to as “Lilly Japan”) today announced that Lilly Japan will transfer the marketing authorization holder for the humanized anti EGFR monoclonal antibody, PORTRAZZA(generic name:necitumumab), in Japan to Nippon Kayaku based upon the contract between both companies which was already announced on April 22nd.

Under this contract, after completing the necessary procedures at Ministry of Health, Labour and Welfare, the transfer is scheduled to take place on August 1st 2019.After the transfer, Nippon Kayaku will be responsible for the marketing authorization of PORTRAZZA and preparing for the launch.


[Please direct inquiries regarding this matter to:]
Telephone: +81- 3- 6731- 5237
Public Relations & Investor Relations Division
Nippon Kayaku Co., Ltd.
PageTop
Corporate Vision
Our Business
Corporate Information
Global Netowork
Investor Relations
CSR